# Dong-A ST Co., Ltd.

Organization · id `cardio:org-dong-a-st-co-ltd` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Dong-A+ST+Co.%2C+Ltd.>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 10 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Dong-A ST Co., Ltd.
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients (`cardio:ct-nct01278498`)
- Sponsors: Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia (`cardio:ct-nct02280590`)
- Sponsors: The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy (`cardio:ct-nct02433119`)
- Sponsors: A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin (`cardio:ct-nct02946541`)
- Sponsors: Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes (`cardio:ct-nct02949193`)
- Sponsors: Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (`cardio:ct-nct04356742`)
- Sponsors: A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin (`cardio:ct-nct04706637`)
- Sponsors: Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION) (`cardio:ct-nct05845489`)
- Sponsors: Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (`cardio:ct-nct06290349`)
- Sponsors: A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH) (`cardio:ct-nct06627322`)

## Provenance

Content hash: dbe52e8da8abb140bdaf35346c5e9d6a4be818349d3e074558b2838089beac68
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
